named programs · 2 · from sources
What they call their work
High-Risk Pancreatic Screening Clinic
Provides screening and risk assessment services including genetic testing, MRI, MRCP, and endoscopic ultrasound for individuals with family history or genetic risk factors for pancreatic cancer.
PRECEDE Consortium
International collaborative network of over 65 academic medical centers pooling clinical data and biospecimens from high-risk individuals to advance research in pancreatic cancer early detection and prevention.
activities · 2 groups
What they do
-
Pancreatic Cancer Research and Support 4 activities
- Assembling and maintaining a cohort of high-risk individuals for researchHas assembled a cohort of over 12,000 high-risk individuals with family history or genetic risk factors for pancreatic cancer, including longitudinal clinical data and biospecimen tracking, to support research and surveillance efforts.
- Conducting research on biomarkers, genetics, and imaging for early detectionConducts research focused on early detection, screening, and prevention of pancreatic cancer, with emphasis on genetic risk assessment, biomarkers, and imaging technologies. Operates the PRECEDE Consortium to advance these goals through scientific collaboration and data sharing.
- Expanding early detection programs internationallyExpanded operations to include a new site in Hungary, where 87 patients were enrolled in the PRECEDE pancreatic cancer early detection study, contributing to international research and surveillance efforts.
- Providing public and patient educational resourcesOffers informational resources on pancreatic cancer screening, diagnosis, treatment, diet, exercise, and emotional well-being. Maintains a news and events page featuring articles, videos, and updates related to pancreatic cancer. Raises awareness through expert media features.
-
-
Cancer Research Funding 3 activities
- Funding centralized data and biospecimen infrastructure for high-risk pancreatic cancer researchFinances centralized data and biospecimen repositories that support access to the world's largest database of individuals at high risk for pancreatic cancer, enabling research on genetics, biomarkers, and imaging for early detection.
- Funding pancreatic cancer early detection research through the PRECEDE ConsortiumFunds academic medical centers and trial sites participating in the PRECEDE Consortium, an international collaboration of 35 hospitals and institutions focused on improving risk assessment, early detection, and prevention of pancreatic cancer. Provides research assistance, funding for trial sites, and resources for clinicians, scientists, genetic counselors, and study coordinators.
- Supporting annual screening and surveillance for high-risk individualsFunds and supports an annual screening and surveillance program for individuals at highest risk of developing pancreatic cancer, including enrollment and consent of high-risk participants in the PRECEDE study.
-
financials · form 990 · fy2024
revenue
Total revenue$1.25M
Contributions & grants$1.13M91%
Program service revenue$54K4%
Investment income$00%
Other revenue$59K
expenses
Total expenses$1.57M
Program expenses94%
Admin / overhead6%
Fundraising0%
Salaries & benefits$446K
Grants paid out$0
Largest expense lineCompensation
balance sheet
Total assets$607K
Cash$475K
Investments$0
Liabilities$48K
Net assets$559K
Liquid reserves3.6 mo
4 years on record · 2020–2024 · YoY revenue -10.3%
leadership · form 990 part vii · fy2024
Who runs it
paid leadership · 2
| Name | Title | Hours/wk | Compensation |
|---|---|---|---|
| Ronald Horvat | Executive Dir. | 40 | $239K |
| Debbie Brandel | VP of Operations | 40 | $174K |
board members · 9
- Daniel Karlsberg — Board Member
- Doug Frankel — Board Member
- Garry Lowe — Board Member
- Jamie Brickell — President
- Laurie MacCaskill — Board Member
- Lyle Jackson — Board Member
- Michael Gershenson — Board Member
- Skip Trachtman — Board Member
- Victoria Manax — Board Member
relationships · 12
Who they work with
- All Our Sponsors And Partners Partner — Collaborates with sponsors and partners in support of pancreatic cancer early detection initiatives.
- Dr. Diane Simeone Partner — Founder of PRECEDE Foundation and recognized leader in pancreatic cancer research.
- HealthyWomen Partner — Featured Dr. Diane Simeone in an article to raise awareness about pancreatic cancer.
- Institute of Pancreatic Diseases at Semmelweis University Partner — Partner institution in Budapest, Hungary, collaborating on the PRECEDE pancreatic cancer early detection initiative.
- National Association for Pancreatic Cancer Patients Partner — Partner organization in Hungary receiving program information to support awareness and enrollment in the PRECEDE study.
- National Federation of Cancer Patients Partner — Partner organization in Hungary receiving program information to support awareness and enrollment in the PRECEDE study.
- PRECEDE Consortium Partner — Collaborates with the PRECEDE Consortium to support pancreatic cancer early detection research.
- Pancreatic Cancer Early Detection Program Consortium Partner — Collaborative partner focused on pancreatic cancer risk assessment, early detection, and prevention
- Revolution Medicines Partner — Collaborates on pancreatic cancer research and initiatives.
- UC San Diego Moores Cancer Center Government — Headquarters of the PRECEDE Consortium and one of only 65 NCI-designated Comprehensive Cancer Centers in the U.S.
- UVA Comprehensive Cancer Center Partner — Collaborates with PRECEDE Foundation in a clinical trial to improve pancreatic cancer early detection.
- global research institutions Partner — Collaborates with global research institutions to accelerate progress in early detection of pancreatic cancer.
strategies · 3
How they approach the work
Named approaches extracted from this org’s sources. Where others share an approach, follow it to see the full set of orgs running it.
- Collaborative Research Network Modelmethodology: collaborative_research_networkBy uniting leading academic, clinical, and industry partners in a global, open network, PRECEDE accelerates the discovery and development of early detection methods for pancreatic cancer because collective expertise and shared goals reduce duplication and increase scientific velocity.
- Open Science and Centralized Data Sharingmethodology: collaborative-data-sharingBy centralizing and openly sharing data and biospecimens from high-risk populations, PRECEDE enables faster identification of biomarkers and screening tools because broad access to standardized, high-quality datasets accelerates validation and innovation across the research community.
- Translational Research Accelerationmethodology: translational_researchBy aligning research funding and collaboration around translational pathways, PRECEDE shortens the timeline from discovery to clinical application because coordinated development prioritizes tools and biomarkers with near-term potential to improve early detection and survival.